Research Paper Volume 16, Issue 3 pp 2563—2590
Integrative analysis confirms TPX2 as a novel biomarker for clinical implication, tumor microenvironment, and immunotherapy response across human solid tumors
Figure 5. Mutation characteristic of TPX2 in different cancer types. (A) The frequency of TPX2 mutations with mutation type across TCGA cancers by cBioPortal. Red represents amplicaion. Green represents mutation. Purple represents structural variant. Grey represents multiple alterations. (B) OncoPrint visual summary of alterations in a query of TPX2 by cBioPortal. (C) Mutation site of TPX2 displayed by cBioPortal. (D) Corresponding 3D structures of TPX2 displayed by cBioPortal. (E–H) The associations of pan-cancer TPX2 mutation status with OS, DSS, DFS and PFS by cBioPortal. (I–K) The associations of TPX2 mutation status with OS of UCEC patients (I) and survival of LUSC patients ((J) PFS; (K) DFS) by cBioPortal. p-value < 0.05 was considered statistically significant.